Search Results
Jun 21, 2026, 20:00 ET Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma
bortezomib and dexamethasone [PVd] or daratumumab, pomalidomide and dexamethasone [DPd]). The primary endpoint of the study is progression-free survival (PFS) assessed by the Independent Review Committee (IRC).Clinical data presented at the American Society of Hematology (ASH) Annual Meeting on December
More news about: Innovent Biologics
Jun 18, 2026, 11:00 ET Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress
49.1%.Among the 31 post-IO patients evaluable for efficacy, cORR and DCR were 29.00% and 77.40%, respectively. Median PFS was 4.0 months and median DoR was 9.1 months. Median OS has not yet been reached. The 12-month OS rate was 76.6% and the 24-month OS rate was 51.1%.
More news about: Mabwell
Jun 18, 2026, 08:47 ET A New Zealand Goldfield Is Quietly Becoming a Critical-Minerals Story -- and the Drills Are Running 24/7
PEA completed, the exploration team intensified the drill-out program, along with the extensive geotechnical data collection required to inform the PFS," said Robert Eckford, Chief Executive Officer of RUA GOLD. "It is exciting to see, at the half-way stage, the drilling progress ahead of schedule, infill
More news about: USA News Group
Jun 18, 2026, 06:30 ET MAYFAIR GOLD REPORTS FINAL POSITIVE RESULTS AND ANALYSIS FROM GRADE CONTROL DRILLING PROGRAM
Study (the "PFS") is to develop the project under the provincial permitting process, targeting the higher-grade 1 million ounce probable mineral reserve (25.1Mt at an average grade of 1.29g/t) sitting near-surface, highlighting the optionality and scalability provided by the deposit. The PFS also outlines
More news about: Mayfair Gold Corp.
Jun 17, 2026, 08:45 ET A Fully Permitted Gold Project in Tanzania Is Quietly Building the Team to Actually Mine It
therefore is not independent of the Company. Cautionary Note on Production Decision: Although Imwelo has been the subject of JORC-compliant PEA, PFS and updated PFS work, these foreign-code studies are not current under NI 43-101. The Company has not completed a feasibility study on Imwelo that establishes
More news about: USA News Group
Jun 17, 2026, 07:00 ET Thesis Gold & Silver Commences 2026 Exploration and Project Advancement Programs at Lawyers-Ranch Project
build on the Prefeasibility Study ("PFS")1 announced in December 2025 that outlined an open pit and underground operation with a 15-year mine life, an after-tax NPV5% of C$2.37 billion, an after-tax IRR of 54.4% and a payback period of 1.1 years. The PFS base case assumed gold and silver prices
More news about: Thesis Gold & Silver Inc.
Jun 16, 2026, 11:54 ET Tiger BioSciences: New National Wound Care Survey Signals Access Crisis Following 2026 CMS CAMPs Payment Change
widespread disruption across wound care delivery settings following the Centers for Medicare & Medicaid Services (CMS) 2026 Physician Fee Schedule (PFS) update establishing a fixed reimbursement rate for cellular, acellular, and matrix-like products (CAMPs). The survey findings were published online
More news about: Tiger BioSciences
Jun 15, 2026, 12:31 ET EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsight
challenge.Currently, osimertinib continues to serve as the global standard of care for EGFR-mutant NSCLC, supported by robust progression-free survival (PFS) and overall survival (OS) benefits along with extensive regulatory approvals across multiple disease stages. At the same time, amivantamab
More news about: DelveInsight Business Research, LLP
Jun 15, 2026, 09:15 ET Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
progression-free survival (PFS) for patients treated with ozekibart compared to placebo. Ozekibart achieved a 52% reduction in the risk of disease progression or death compared to placebo (stratified Hazard Ratio [HR] 0.479; 95% CI: 0.33, 0.68; P<0.0001), more than doubling median PFS to 5.52 months versus
More news about: Inhibrx Biosciences, Inc.
Jun 14, 2026, 03:15 ET Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
endpoint of IRC-assessed PFS was significantly improved with the addition of pirtobrutinib to VR compared to VR alone (HR=0.55 [95% CI, 0.40-0.75]; p=0.0001). Median PFS in the PVR arm was not reached (95% CI, 43.3-NE), versus 39.7 months (95% CI, 35.9-NE) in the VR arm. The PFS results were consistent
More news about: Eli Lilly and Company
Jun 13, 2026, 06:33 ET New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
results showed significant improvement in PFS for Tal-DP (hazard ratio [HR], 0.28; 95 percent confidence interval [CI], 0.20-0.40; p<0.0001) and Tal-D (HR, 0.33; 95% CI, 0.24-0.46; p<0.0001). At 24 months, Tal-DP showed a PFS rate of 81.3% and Tal-D showed a PFS rate of 77.6%.1 All participants
More news about: Johnson & Johnson
Jun 12, 2026, 08:00 ET Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
Zepzelca and atezolizumab combination demonstrated a statistically significant improvement in the primary endpoints of OS and progression-free survival (PFS), as assessed by an independent review facility, compared to treatment with atezolizumab alone. The Zepzelca and atezolizumab combination reduced
More news about: Jazz Pharmaceuticals plc
Jun 12, 2026, 03:00 ET AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
years.1After a median follow-up of 9.2 years, treatment with venetoclax plus obinutuzumab resulted in superior PFS compared to the obinutuzumab plus chlorambucil group, with median PFS of 6.4 years versus 3.2 years, respectively (HR 0.50 [95% CI 0.39-0.63], p<0.001). The most frequently occurring
More news about: AbbVie
Jun 12, 2026, 03:00 ET AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
years.1After a median follow-up of 9.2 years, treatment with venetoclax plus obinutuzumab resulted in superior PFS compared to the obinutuzumab plus chlorambucil group, with median PFS of 6.4 years versus 3.2 years, respectively (HR 0.50 [95% CI 0.39-0.63], p<0.001). The most frequently occurring
More news about: AbbVie
Jun 11, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
locally advanced or metastatic melanoma" "did not each statistical significance for the primary endpoint of improvement in progression-free survival (PFS) compared to pembrolizumab (PD-1 inhibitor) monotherapy."On this news, Regeneron's stock price fell $68.57 per share, or 9.82%, to close at $629.68
More news about: Pomerantz LLP
Jun 11, 2026, 07:00 ET Grounded Lithium Provides Spring 2026 Operational Update
releases, the Company and Denison are progressing the completion of the pre-feasibility study ("PFS") for the KLP. Now at the review stage and assuming positive technical, operational and economic conclusions, the PFS will serve as the basis for important next steps in the journey to bring the KLP to a
More news about: Grounded Lithium Corp.
Jun 11, 2026, 02:20 ET CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights
anti-tumor activity.Industry challenge: Historically, most anti-VEGF plus PD-(L)1 regimens have primarily improved progression-free survival (PFS), while overall survival (OS) benefits remains highly uncertain. By incorporating a CTLA-4 mechanism, CS2009 aims to break through this limitation.2.
More news about: CStone Pharmaceuticals
Jun 09, 2026, 06:15 ET Uranium Energy Corp Reports Results for the Third Quarter of Fiscal 2026
completed. Roughrider Pre-Feasibility Progressing: Core drilling is over 80% complete to support a planned pre-feasibility study ("PFS") for the world class Roughrider Project located in the Athabasca Basin of Saskatchewan, Canada.United States Uranium Refining &
More news about: Uranium Energy Corp
Jun 08, 2026, 08:00 ET AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
study showed a statistically significant improvement in PFS versus investigator's choice of chemoimmunotherapy (CIT) — either rituximab plus gemcitabine plus oxaliplatin or bendamustine plus rituximab (HR 0.74 [95% CI, 0.60–0.92]; P=0.0059; 24-month PFS: 30% vs 13%). The study did not demonstrate a statistically
More news about: AbbVie
Jun 08, 2026, 08:00 ET AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
study showed a statistically significant improvement in PFS versus investigator's choice of chemoimmunotherapy (CIT) — either rituximab plus gemcitabine plus oxaliplatin or bendamustine plus rituximab (HR 0.74 [95% CI, 0.60–0.92]; P=0.0059; 24-month PFS: 30% vs 13%). The study did not demonstrate a statistically
More news about: AbbVie
Jun 08, 2026, 05:45 ET Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
RAS and RAF wild-type advanced colorectal cancer who have progressed after standard second-line therapy, achieved a median progression-free survival (PFS) of 5.5 months, compared to 2.8 months with standard-of-care (SOC), suggesting a potential new treatment option for patients whose disease has progressed
More news about: Hengrui Pharma
Jun 05, 2026, 10:00 ET Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval
100%, with a mOS of 40.7 months.6In terms of long-term clinical benefits, Eratrectinib also achieved impressive results in PFS and DOR. The 2-year PFS rate stood at 75.7% and the 2-year DOR rate hit 85.5%, fully proving that the drug can deliver sustained disease control and long-term remission
More news about: Vcare PharmaTech
Jun 04, 2026, 22:45 ET WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
and Manufacturing Science and Technology (MSAT) labs, significantly expanding the Company's end-to-end DP capabilities. With three pre-filled syringe (PFS) lines and two vial lines for liquid and lyophilized products, it will deliver integrated DP manufacturing for multiple dosage forms across clinical
More news about: WuXi Biologics
Jun 04, 2026, 16:39 ET Lupin Receives Approval from U.S. FDA for Ranluspec™(ranibizumab) Injection
Ranluspec™ is the only interchangeable biosimilar ranibizumab approved in the United States in both vials and pre-filled syringes (PFS). Both the vial and PFS presentations are approved in both strengths available for Lucentis®, 0.3 mg (0.05 mL of 6 mg/mL), and 0.5 mg (0.05 mL of 10 mg/mL). Ranibizumab
More news about: Lupin Pharmaceutical, Inc.
Jun 04, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
locally advanced or metastatic melanoma" "did not each statistical significance for the primary endpoint of improvement in progression-free survival (PFS) compared to pembrolizumab (PD-1 inhibitor) monotherapy." On this news, Regeneron's stock price fell $68.57 per share, or 9.82%, to close at $629.68
More news about: Pomerantz LLP